

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 16, 2006

ANGIODYNAMICS, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

0-50761
(Commission File Number)

11-3146460
(IRS Employer Identification No.)

603 Queensbury Avenue, Queensbury, New York
(Address of Principal Executive Offices)

12804
(Zip Code)

(518) 798-1215
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.01. Entry into a Material Definitive Agreement

On January 18, 2006, in connection with the election on January 16, 2006, of Peter J. Graham as a director of AngioDynamics, Inc. (the "Company"), the Company granted Mr. Graham an option under the Company's 2004 Stock and Incentive Award Plan for 25,000 shares of the Company's common stock. The option is exercisable at \$28.43 per share and vests in four equal installments of 6,250 shares on the first four anniversaries of the grant date. Mr. Graham will also receive the standard compensation payable to all directors, consisting of an annual cash retainer of \$24,000, board meeting fees of \$1,500 per meeting, meeting fees of \$750 per meeting for any committee to which he may be appointed, and the annual option grant for 6,000 shares of common stock made to each director following the end of the Company's fiscal year.

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

(d) On January 16, 2006, the Company's Board of Directors (the "Board") elected Peter J. Graham as a Class III director of the Company, effective immediately, for a term expiring at the 2006 annual meeting of stockholders, to fill the vacancy created by the death on December 28, 2005, of Howard S. Stern. Mr. Graham was the son-in-law of Mr. Stern, and is Senior Vice President-Chief Legal Officer, Global Human Resources and Secretary of E-Z-EM Inc., the Company's former parent company. He served as corporate counsel and secretary of the Company from 1997 until its spin-off by E-Z-EM in October, 2004. There are no arrangements or understandings between Mr. Graham and any persons pursuant to which he was selected as a director. The Board has not yet determined the committees of the Board, if any, on which Mr. Graham will serve. There are no transactions between the Company and Mr. Graham that are reportable under Item 404(a) of Regulation S-K. On January 17, 2006, the Company issued a press release announcing Mr. Graham's election, a copy of which is attached as Exhibit 99.1. hereto.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

- 10.1 Summary of the Compensation of the Directors of AngioDynamics, Inc. (incorporated by reference to exhibit 10.1 to the registrant's quarterly report on Form 10-Q/A for the quarterly period ended February 26, 2005).
- 10.2 AngioDynamics, Inc., 2004 Stock and Incentive Award Plan (incorporated by reference to exhibit 10.18 to the registrant's registration statement on Form S-1, Commission file no. 333-113329).
- 10.3 Form of Non-Statutory Stock Option Agreement (incorporated by reference to exhibit 10.1 to the registrant's quarterly report on Form 10-Q for the quarterly period ended August 28, 2004).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 20, 2006

ANGIODYNAMICS, INC.
(Registrant)

By: /s/ Joseph G. Gerardi
Joseph G. Gerardi
Vice President, Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description</u>
10.1	Summary of the Compensation of the Directors of AngioDynamics, Inc. (incorporated by reference to exhibit 10.1 to the registrant's quarterly report on Form 10-Q/A for the quarterly period ended February 26, 2005).
10.2	AngioDynamics, Inc., 2004 Stock and Incentive Award Plan (incorporated by reference to exhibit 10.18 to the registrant's registration statement on Form S-1, Commission file no. 333-113329).
10.3	Form of Non-Statutory Stock Option Agreement (incorporated by reference to exhibit 10.1 to the registrant's quarterly report on Form 10-Q for the quarterly period ended August 28, 2004).
<u>99.1</u>	<u>Press Release issued by AngioDynamics, Inc. on January 17, 2006.</u>

**Company Contacts:**

AngioDynamics, Inc.
 Jennifer Chase
 518-798-1215 ext. 370
www.angiodynamics.com

Investor Relations Contacts:

Lippert/Heilshorn & Associates, Inc.
 Kim Sutton Golodetz (kgolodetz@lhai.com)
 (212) 838-3777
 Bruce Voss (bvoss@lhai.com)
 (310) 691-7100

ANGIODYNAMICS APPOINTS PETER J. GRAHAM TO BOARD OF DIRECTORS

QUEENSBURY, N.Y. (January 17, 2006) – AngioDynamics, Inc. (Nasdaq: ANGO) announced that Peter J. Graham, 39, was named to its board of directors effective January 16, 2006. Mr. Graham fills the seat previously held by Howard S. Stern, who passed away late last year. Mr. Graham, who was Mr. Stern's son-in-law, will hold this appointment for the remainder of Mr. Stern's term, which expires at the Annual Shareholder meeting in October 2006.

Mr. Graham served as corporate counsel and Secretary of AngioDynamics, Inc. from 1997 until its separation from E-Z-EM, Inc (NASDAQ: EZEM) in 2004. E-Z-EM, Inc is the former parent company of AngioDynamics. Mr. Graham has held several different management positions at E-Z-EM and is presently the Senior Vice President – Chief Legal Officer, Global Human Resources and Secretary for E-Z-EM. A member of the American Bar Association, the New York State Bar Association and the American Corporate Counsel Association, he has been practicing in the area of general corporate, intellectual property and securities law for medical technology companies for almost ten years.

Paul S. Echenberg, chairman of the board of directors commented, "We are fortunate to be able to tap the knowledge and experience that Peter will bring to AngioDynamics. His familiarity with the Company and the interventional radiology and vascular surgery markets in which it operates, will serve the Company well. Peter's legal experience in the medical device arena along with his understanding of the challenges that face public companies in today's regulatory environment is welcome. Over the years, Peter has made significant contributions to AngioDynamics and I am very excited that we will be able to continue to benefit from his expertise."

Mr. Graham received his J.D. Degree from the Benjamin N. Cardozo School of Law in New York City and his B.A. in Political Science from the University of Wisconsin – Madison.

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic catheters, hemodialysis catheters, endovascular laser venous system products, PTA dilation balloon catheters, image-guided vascular access products, thrombolytic products and drainage products.

###